Shares of Jubilant Pharmova Ltd rose 1.73% to ₹880 on Thursday, March 13, after the company announced that its subsidiary, Jubilant Cadista Pharmaceuticals Inc., received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA).
The solid oral formulations facility in Salisbury, Maryland, USA, was inspected by the USFDA in January 2025, and the regulatory filing confirms that the inspection has been successfully closed. However, the facility is not expected to manufacture any products, as its operations were previously shut down on April 18, 2024.
Jubilant Pharmova received the official communication from USFDA on March 11, 2025, at 09:27 PM IST. The VAI status indicates that the facility is compliant with regulatory requirements and that no further regulatory action is required at this time.
Despite the facility closure, the positive regulatory outcome is seen as a boost for Jubilant Pharmova, as it helps maintain compliance with USFDA norms, which is critical for its future business prospects in the US pharmaceutical market.
